Efficacy and safety of raltegravir in treatment-experienced HIV-1-infected patients switching from enfuvirtide-based regimens: 48 week results of the randomized EASIER ANRS 138 trial-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Efficacy and safety of raltegravir in treatment-experienced HIV-1-infected patients switching from enfuvirtide-based regimens: 48 week results of the randomized EASIER ANRS 138 trial

Published:2011-06-28 Issue:9 Volume:66 Page:2099-2106
ISSN:1460-2091
Container-title:Journal of Antimicrobial Chemotherapy
language:en
Short-container-title:

Author:

Gallien Sébastien¹²,Braun Joséphine³,Delaugerre Constance²⁴,Charreau Isabelle³,Reynes Jacques⁵,Jeanblanc François⁶,Verdon Renaud⁷,de Truchis Pierre⁸,May Thierry⁹,Madelaine-Chambrin Isabelle¹⁰,Aboulker Jean-Pierre³,Molina Jean-Michel¹²,Balkau B.,Bourlière M.,Calvez V.,Korzek M.,Sereni D.,

Affiliation:

1. Department of Infectious Diseases, Assistance Publique Hôpitaux de Paris, Saint-Louis Hospital, Paris, France

2. University of Paris-Diderot Paris 7, Paris, France

3. INSERM SC10, Villejuif, France

4. Laboratory of Virology, Saint-Louis Hospital, Paris, France

5. Department of Infectious Diseases, Gui de Chauliac University Hospital, Montpellier, France

6. Department of Internal Medicine, E. Herriot Hospital, Lyon, France

7. Department of Infectious Diseases, Côte de Nacre Hospital, Caen, France

8. Department of Infectious Diseases, Raymond Poincaré Hospital, Garches, France

9. Department of Infectious Diseases, Brabois Hospital, Nancy, France

10. Pharmacy, Saint-Louis Hospital, Paris, France

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology,Microbiology (medical)

Link

http://academic.oup.com/jac/article-pdf/66/9/2099/16862630/dkr269.pdf

Reference20 articles.

1. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial;Lennox;Lancet,2009

2. Raltegravir versus efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses;Lennox;J Acquir Immune Defic Syndr,2010

3. Raltegravir with optimized background therapy for resistant HIV-1 infection;Steigbigel;N Engl J Med,2008

4. Long-term efficacy and safety of raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials;Steigbigel;Clin Infect Dis,2010

5. Switch to a raltegravir-based regimen versus continuation of a lopinavir–ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials;Eron;Lancet,2010

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and Safety of Raltegravir-Based Dual Therapy in AIDS Patients: A Meta-Analysis of Randomized Controlled Trials;Frontiers in Pharmacology;2019-10-17

2. Metabolic, mitochondrial, renal and hepatic safety of enfuvirtide and raltegravir antiretroviral administration: Randomized crossover clinical trial in healthy volunteers;PLOS ONE;2019-05-23

3. Integrase Inhibitors: After 10 Years of Experience, Is the Best Yet to Come?;Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy;2019-04

4. Similar long-term efficacy of dual therapy containing raltegravir and a boosted protease inhibitor versus standard triple therapies in pretreated HIV-1-infected patients in a retrospective, real-life cohort of 14 years;HIV Medicine;2018-07-03

5. The treatment outcomes of antiretroviral substitutions in routine clinical settings in Asia; data from the TREAT Asia HIV Observational Database (TAHOD);Journal of the International AIDS Society;2017-12

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3